Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer.
about
Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects.Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.Immunotherapy for prostate cancer: an emerging treatment modality.Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.DNA vaccination for prostate cancer: key concepts and considerations.The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance.Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse.NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect.Organ specific Gst-pi expression of the metastatic androgen independent prostate cancer cells in nude mice.DNA vaccination for prostate cancer, from preclinical to clinical trials - where we stand?Reactive oxygen species induction by cabazitaxel through inhibiting Sestrin-3 in castration resistant prostate cancer.Current Progress in EBV-Associated B-Cell Lymphomas.siRNA-Mediated Silencing of CIP2A Enhances Docetaxel Activity Against PC-3 Prostate Cancer Cells.
P2860
Q37303584-3B2DD44F-9626-4A62-AA6B-5FCB47818C4BQ37622701-28EA5E81-9802-4633-A314-AB2722842F08Q37691634-B482F1D1-3598-440C-B62D-9AAF1BCE3C52Q37737611-46E27465-7744-4B5F-A7D0-001C0A729EBEQ38544772-F608153C-F796-4E5F-93FA-62B1F7E6ECDCQ38681199-8641B02E-8010-420C-9FD9-D081B94AB2D0Q38780080-9954389E-0465-4F86-AA7D-592FEB7D27AFQ38918211-6275A816-7F9F-4182-874C-79C06BECBA2AQ39508284-C2E70A33-055A-4E3F-9864-D5B8751CB98DQ41561252-62F5EA3B-B840-4897-B216-CA5761C29E75Q46258836-4E512331-61FD-47E1-B071-D908B88822ADQ47606345-2E96A257-4E14-48CB-A013-800055AD3845Q49332481-CC8EC89F-C58D-4875-8581-6320F036FD8C
P2860
Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Docetaxel chemotherapy remains ...... ion-resistant prostate cancer.
@en
Docetaxel chemotherapy remains ...... ion-resistant prostate cancer.
@nl
type
label
Docetaxel chemotherapy remains ...... ion-resistant prostate cancer.
@en
Docetaxel chemotherapy remains ...... ion-resistant prostate cancer.
@nl
prefLabel
Docetaxel chemotherapy remains ...... ion-resistant prostate cancer.
@en
Docetaxel chemotherapy remains ...... ion-resistant prostate cancer.
@nl
P356
P1476
Docetaxel chemotherapy remains ...... ion-resistant prostate cancer.
@en
P2093
Brian Schurko
P304
P356
10.1038/NCPONC1201
P577
2008-07-22T00:00:00Z